| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
4 companies
Bhanji Muna is a Director at ARDX with holdings across 4 companies. Recent SEC Form 4 filings include 0 buys and 10 sells.
Estimated insider holdings value: $4.7M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 13, 2025 | VCYT Veracyte, Inc. | Director | Sell | 4,589 | $26.67 | $122,366.60 | -13.3% | +20.5% | - | |
| May 15, 2025 | CYTK Cytokinetics Inc | Director | Sell | 1,454 | $29.73 | $43,227.42 | -5.8% | +23.6% | - | |
| Apr 29, 2025 | NTLA Intellia Therapeutics, Inc. | Director | Sell | 265 | $8.50 | $2,252.50 | -1.4% | +59.9% | - | |
| Jan 29, 2025 | NTLA Intellia Therapeutics, Inc. | Director | Sell | 265 | $9.97 | $2,642.05 | -1.3% | -19.0% | +37.4% | |
| Jun 10, 2024 | VCYT Veracyte, Inc. | Director | Sell | 3,870 | $20.32 | $78,633.76 | -14.3% | +39.3% | +33.5% | |
| Jun 10, 2024 | CYTK Cytokinetics Inc | Director | Sell | 2,000 | $52.07 | $104,140.00 | -10.2% | +3.1% | -36.2% | |
| May 28, 2024 | VCYT Veracyte, Inc. | Director | Sell | 1,539 | $21.00 | $32,319.00 | -5.4% | +50.7% | +24.6% | |
| Oct 31, 2023 | NTLA Intellia Therapeutics, Inc. | Director | Sell | 265 | $23.90 | $6,333.50 | -2.2% | +4.5% | -42.8% | |
| Jul 31, 2023 | NTLA Intellia Therapeutics, Inc. | Director | Sell | 265 | $42.33 | $11,217.45 | -2.1% | -43.7% | -37.9% | |
| Jul 7, 2023 | CYTK Cytokinetics Inc | Director | Sell | 2,000 | $34.12 | $68,234.60 | -12.5% | -20.9% | +59.9% |